AtriCure director sells 5,313 shares at $54.22

AtriCure, Inc. (ATRC) director Regina E. Groves reported selling 5,313 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted average price of $54.22 per share.

Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) director Regina E. Groves reported selling 5,313 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted average price of $54.22 per share. The trades were executed between $54.09 and $54.38 per share, leaving her with 34,546 shares held directly. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 5,313 shares

Net Sell 1 txn

Insider GROVES REGINA E

Role Director

Sold 5,313 shs ($288K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,313	$54.22	$288K

Holdings After Transaction: Common Stock — 34,546 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 5,313 shares Weighted average sale price: $54.22 per share Price range for trades: $54.09–$54.38 per share +1 more

4 metrics

Shares sold 5,313 shares Common stock sold by director Regina E. Groves on September 11, 2026

Weighted average sale price $54.22 per share Reported sales price for the 5,313-share transaction

Price range for trades $54.09–$54.38 per share Range of individual trade prices within the reported sale

Shares held after transaction 34,546 shares Direct holdings of Regina E. Groves following the sale

Key Terms

weighted average sales price, open market or private transaction, reporting person

3 terms

weighted average sales price financial

"The price reported above reflects the weighted average sales price"

open market or private transaction financial

"Sale in open market or private transaction"

reporting person regulatory

"The reporting person hereby undertakes to provide upon request"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) disclose in this Form 4?

AtriCure reported that director Regina E. Groves sold 5,313 shares of common stock on September 11, 2026 in a sale characterized as an open-market or private transaction.

At what price did the AtriCure (ATRC) director sell shares?

The sale was reported at a weighted average price of $54.22 per share, with multiple trades executed in a price range from $54.09 to $54.38 per share.

How many AtriCure (ATRC) shares does Regina E. Groves hold after the sale?

After the reported sale, Regina E. Groves holds 34,546 shares of AtriCure common stock directly, according to the Form 4 disclosure.

What was the size of the AtriCure (ATRC) insider sale on September 11, 2026?

The transaction involved the sale of 5,313 shares of AtriCure common stock by director Regina E. Groves on September 11, 2026.

Was the AtriCure (ATRC) insider sale made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, and no footnote indicates that the 5,313-share sale by Regina E. Groves was made under a Rule 10b5-1 trading plan.

What type of transaction did the AtriCure (ATRC) Form 4 report?

The Form 4 reports a sale of common stock coded as a sale in an open market or private transaction by director Regina E. Groves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 05:45 PM Accepted by SEC EDGAR 09/14/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROVES REGINA E

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		5,313	D	$54.22(1)	34,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Regina E. Groves	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)